Journal ArticleDOI
Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin.
Luigi Fiume,Ferruccio Bonino,Alessandro Mattioli,E. Chiaberge,MariaR Torrani Cerenzia,Corrado Busi,MauriziaR Brunetto,Giorgio Verme +7 more
Reads0
Chats0
TLDR
To examine whether its monophosphate ester (ara-AMP) can be effective in the treatment of chronic hepatitis B when given in reduced dosage as a conjugate with lactosaminated human serum albumin (L-HSA), which selectively enters hepatocytes, five patients with chronic type B hepatitis were treated with the conjugates.About:
This article is published in The Lancet.The article was published on 1988-07-02. It has received 79 citations till now. The article focuses on the topics: HBeAg & HBsAg.read more
Citations
More filters
Journal ArticleDOI
The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery
TL;DR: The biorecognition between lectinised drug delivery systems and glycosylated structures in the intestine can be exploited for improved peroral therapy to improve absorption and probably bioavailability of poorly absorbable drugs, peptides and proteins as well as therapeutic DNA.
Journal ArticleDOI
Glycoconjugates as carriers for specific delivery of therapeutic drugs and genes
TL;DR: The main properties of neoglycoproteins and glycosylated polymers have been developed to study the properties of endogenous lectins and to carry various drugs and their efficiency in targeting genes in comparison with that of other available targeted transfection methods is discussed.
Journal ArticleDOI
Receptor mediated glycotargeting
Manpreet S. Wadhwa,Kevin G. Rice +1 more
TL;DR: It may be concluded that the discovery of new mammalian lectins which endocytose their ligands will lead to the rapid development of new glycotargeting agents founded on the principles of carbohydrate-protein interactions.
Patent
Prodrugs phosphorus-containing compounds
TL;DR: Prodrugs of formula I, their uses, their intermediates, and their method of manufacture are described in this article, where the authors also present a method for their extraction.
Journal ArticleDOI
Liver-Targeted Drug Delivery Using HepDirect Prodrugs
Mark D. Erion,Paul D. van Poelje,Deidre A. MacKenna,Timothy J. Colby,Annika C. Montag,James M. Fujitaki,David L. Linemeyer,David A. Bullough +7 more
TL;DR: HepDirect prodrugs represent a potential strategy for targeting drugs to the liver and achieving more effective therapies against chronic liver diseases such as hepatitis B, hepatitis C, and hepatocellular carcinoma, and a 5-day safety study in mice demonstrated the toxicological benefits of liver targeting.
References
More filters
Book ChapterDOI
The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins.
Gilbert Ashwell,Anatol G. Morell +1 more
Journal ArticleDOI
Chronic hepatitis in HBsAg carriers with serum HBV-DNA and Anti-HBe
Ferruccio Bonino,Floriano Rosina,M. Rizzetto,Roberto Rizzi,E. Chiaberge,R Tardanico,Francesco Callea,Giorgio Verme +7 more
TL;DR: A positive HBV-DNA test in anti-HBe carriers is associated with a severe and evolutive liver disease and may provide an indication for treatment with drugs inhibiting the synthesis ofHBV- DNA.
Journal ArticleDOI
Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active hepatitis B virus replication in the liver.
TL;DR: The assay for serum HBV DNA appears to be an excellent noninvasive method for detecting active replication of HBV in HBsAg carriers.
Journal ArticleDOI
Proteins containing reductively aminated disaccharides: Synthesis and chemical characterization☆
Barbara A. Schwartz,Gary R. Gray +1 more
TL;DR: It is demonstrated that the expected secondary amine linkages are formed with the ϵ-amino groups of lysine in synthetic glycoproteins prepared and compared with bovine serum albumin conjugates by amino acid analysis after acid hydrolysis.
Journal ArticleDOI
Randomized Controlled Trial of Adenine Arabinoside Monophosphate for Chronic Type B Hepatitis
Jay H. Hoofnagle,Jay H. Hoofnagle,Reginald G. Hanson,Reginald G. Hanson,Gerald Y. Minuk,Gerald Y. Minuk,S. Chris Pappas,S. Chris Pappas,Daniel F. Schafer,Daniel F. Schafer,G. M. Dusheiko,G. M. Dusheiko,Sharon E. Straus,Sharon E. Straus,Hans Popper,Hans Popper,E. Anthony Jones,E. Anthony Jones +17 more
TL;DR: It is suggested that a 4-wk course of adenine arabinoside monophosphate therapy does not induce an increased rate of long-term remissions in chronic type B hepatitis.